Role of Taxane and Anthracycline Combination Regimens in the Management of Advanced Breast Cancer A Meta-Analysis of Randomized Trials

摘要

The clinical benefits provided by using combined taxanes and anthracyclines in first-line chemotherapy for metastatic breast carcinoma (MBC) remain uncertain. This meta-analysis compares the benefits of using a combination of anthracyclines along with taxanes versus using single-agent-based chemotherapeutic regimens in the treatment of MBC.